Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Sponsor: Oncology Specialists, S.C.
Listed as NCT01078922, this PHASE2 trial focuses on Non-Hodgkin Lymphomas and remains terminated or withdrawn. Sponsored by Oncology Specialists, S.C., it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oncology Specialists, S.C.
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .